ChuanChu Chou - Genscript Biotech Executive
| GNNSF Stock | USD 1.37 0.01 0.72% |
Executive
Dr. Chou ChuanChu is Department head Preclinical Drug Development Service Business Segment of the Company. Since January 2014, Dr. Chou was appointed as the department head of the preclinical drug development services segment of our Group. Prior to joining our Group, Dr. Chou served at ScheringPlough as a research fellow from 1988 to 2009. From 2010 to 2011, Dr. Chou was the external collaboration leader of cardiovascular projects of the Global Scientific Strategy Division at Merck Co. . Dr. Chou received a BS in forestry degree in June 1976 and MS in biochemistry degree in June 1980 from National Taiwan University in Taiwan. Dr. Chou received a Doctor of Philosophy in Biology degree from the University of California, Los Angeles in the United States in June 1986. Dr. Chou has not held any directorship in any other public companies the securities of which are or have been listed on any securities market in Hong Kong or overseas in the past three years. since 2014.
| Age | 69 |
| Tenure | 10 years |
| Phone | 86 25 5889 7288 |
| Web | https://www.genscript.com |
Genscript Biotech Management Efficiency
The company has return on total asset (ROA) of (0.1165) % which means that it has lost $0.1165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5574) %, meaning that it generated substantial loss on money invested by shareholders. Genscript Biotech's management efficiency ratios could be used to measure how well Genscript Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sourav Kundu | NextCure | 63 | |
| Perrin BS | Nuvalent | N/A | |
| Lora Pike | Ovid Therapeutics | N/A | |
| Jiang JD | Connect Biopharma Holdings | N/A | |
| Kathleen Farren | Merus BV | N/A | |
| MPH DO | Kronos Bio | 59 | |
| Harold Waitz | Lineage Cell Therapeutics | 82 | |
| Kimberly Freeman | Zentalis Pharmaceuticals Llc | N/A | |
| Deborah JD | Nuvalent | 48 | |
| JD III | Lineage Cell Therapeutics | 43 | |
| Yung MD | Keros Therapeutics | 48 | |
| Srikanth MD | Connect Biopharma Holdings | N/A | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| MPH MD | Ovid Therapeutics | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Wes Trotter | Kronos Bio | N/A | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| Sandra Gardiner | Kronos Bio | 58 | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 |
Genscript Biotech Leadership Team
Elected by the shareholders, the Genscript Biotech's board of directors comprises two types of representatives: Genscript Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genscript. The board's role is to monitor Genscript Biotech's management team and ensure that shareholders' interests are well served. Genscript Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genscript Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shiniu Wei, Chief Officer | ||
| Li Zhu, Vice President - Strategy | ||
| Brian Min, CEO Bus | ||
| Zhenyu Liu, Chief Officer | ||
| Jiange Meng, Vice President - Finance, Executive Director | ||
| Weihui Shao, Chief Officer | ||
| Chifa Zhang, Department head - industry synthetic biology product segment | ||
| ACIS ACS, Company Sec | ||
| Ye MS, Pres CoFounder | ||
| ChuanChu Chou, Department head - Preclinical Drug Development Service Business Segment |
Genscript Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genscript Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.66) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 5.11 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 38.31 % | |||
| Shares Owned By Institutions | 24.68 % | |||
| Price To Earning | 200.00 X | |||
| Price To Book | 6.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.